Nordic microbes A/SAktiv

CVR 42559997

Økonomiske nøgletal

4.894.958 kr.-20,4%
Bruttofortjeneste 2025
+12,7%
Gennemsnitlig vækst pr. år 2022–2025
02 mio.4 mio.6 mio.8 mio.2022202320242025

Nøgletal

2025
Balancens sammensætning
OmsætningsaktiverAnlægsaktiverGæld og hensatte forpligtelserEgenkapital
025 mio.50 mio.75 mio.2022202320242025

Selskabsskat

indkomstår 2024
2024Skattepligtig indkomst -9.232.904 kr.0 kr.
2023Skattepligtig indkomst -2.591.608 kr.0 kr.
Selskabsskat →

Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk

Regnskabstal2022–2025
2022202320242025
Balance — aktiver
Likvide beholdninger2.796.87734.845.83612.350.00821.800.566
Omsætningsaktiver i alt5.304.09438.403.61517.884.48626.567.384
Anlægsaktiver i alt7.784.05413.768.81728.184.58640.999.117
Aktiver i alt13.088.14852.172.43246.069.07267.566.501
Balance — passiver
Kortfristede gældsforpligtelser1.050.7131.490.2311.630.7661.103.202
Langfristede gældsforpligtelser4.160.0000——
Gældsforpligtelser i alt5.210.7131.490.2311.630.7661.103.202
Selskabskapital55.265402.520402.520481.849
Overført resultat4.798.03342.871.60126.537.02038.024.001
Årets resultat-2.161.140-4.526.454-6.523.266-11.315.953
Egenkapital i alt7.877.43550.682.20144.158.93566.298.858
Resultatopgørelse
Bruttofortjeneste3.423.5044.541.5806.147.6174.894.958
Resultat af primær drift-2.880.170-5.878.346-9.801.907-14.947.607
EBITDA-2.646.334-5.076.912-7.808.731-11.266.234
Resultat før skat-3.090.233-5.927.143-8.611.236-14.849.621
Årets resultat-2.161.140-4.526.454-6.523.266-11.315.953
Personaleomkostninger6.069.8389.615.35413.867.45016.161.192
Af- og nedskrivninger233.836801.4341.993.1763.681.373
Andre nøgletal
Ansatte7152022

En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.

Om virksomheden

Årsrapport 2025

Business reviewNordic microbes A/S, formerly Bioomix A/S, is a Danish ag-biotech company that develops, produces, and commercialises microbial products for agriculture. In 2025, Nordic microbes made significant progress towards its mission of making agriculture more productive, profitable, and sustainable through the use of microbial products. The company’s R&D activities focused primarily on the continued development and formulation of SeedSpeed and FungiFoe. This work resulted in the development of a storable powder formulation, for which production was successfully outsourced to an external manufacturing partner. During the year, the company also initiated the regulatory development of its biofungicide and conducted several successful third-party field trials with its products. Commercially, Nordic Microbes increased sales, achieved its first sales in the UK, expanded product use into maize and rapeseed, and initiated discussions and field trials with potential distributors across Europe. The commercial activities were supported by targeted marketing efforts, including customer case stories, video content, and participation in a range of agricultural events and trade shows. To support the company’s continued development, Nordic Microbes successfully raised additional equity and grant financing during the year. Entering 2026, Nordic Microbes is well-positioned for continued development and growth, supported by a strengthened product pipeline, a robust intellectual prope

Financial review The company's income statement for the year ended 31 December 2025 shows a loss of DKK 11.315.953, and the balance sheet at 31 December 2025 shows equity of DKK 66.298.858.

Uddrag af ledelsesberetningen i den seneste årsrapport.

Nordic microbes A/S — cvrprofil.dk